TY - JOUR
T1 - The prevalence of clinically relevant herb-drug interactions between herbal products and anti-cancer therapy in older adults with cancer
T2 - A cross-sectional study
AU - Brokaar, Edwin J.
AU - van den Bos, Frederiek
AU - Portielje, Johanneke E.A.
AU - Visser, Loes E.
N1 - Publisher Copyright: © 2025 The Author(s)
PY - 2025/6
Y1 - 2025/6
N2 - Background: The use of herbal supplements is highly prevalent amongst people with cancer and may lead to clinically relevant herb-drug interactions (HDIs) with their anti-cancer treatment. As the number of older adults with cancer increases, the numbers of older adults with cancer that are at risk of a HDI with anti-cancer treatment increases as well. Objective: The goal of this study was to establish the prevalence of potentially relevant HDIs in older adults who undergo anti-cancer treatment. Also, the overall use of herbal products in this population and possible associations with patient characteristics were investigated. Method: In this single center cross-sectional study patients aged ≥65 years were invited to participate if they underwent systemic anticancer treatment for a solid or hematological cancer. A questionnaire was developed to investigate the use of a selected set of frequently used herbs with known HDIs with regular medications. If a selected herb was used, the herb and oncological medication were assessed for potentially relevant HDIs. All potentially relevant HDIs were independently evaluated by two pharmacists on clinical relevance. Results: A total of 202 patients were included in the analysis. The mean age was 74 years and 54 % was male. The prevalence of potentially relevant HDIs was 4 % and overall herb use was 12 %. Thirteen potentially relevant HDIs were identified, of which 6 were judged to be clinically relevant. The clinically relevant HDIs concerned red yeast rice, red coneflower, turmeric, and cannabis. None of the patient characteristics were associated with overall herb use. Conclusion: Potentially relevant HDIs between herbal supplements and oncological treatment occur in 4 % of older adults with cancer and half of these are clinically relevant. Healthcare providers should question patients with cancer on the use of herbal supplements and monitor for relevant HDI with the treatment given.
AB - Background: The use of herbal supplements is highly prevalent amongst people with cancer and may lead to clinically relevant herb-drug interactions (HDIs) with their anti-cancer treatment. As the number of older adults with cancer increases, the numbers of older adults with cancer that are at risk of a HDI with anti-cancer treatment increases as well. Objective: The goal of this study was to establish the prevalence of potentially relevant HDIs in older adults who undergo anti-cancer treatment. Also, the overall use of herbal products in this population and possible associations with patient characteristics were investigated. Method: In this single center cross-sectional study patients aged ≥65 years were invited to participate if they underwent systemic anticancer treatment for a solid or hematological cancer. A questionnaire was developed to investigate the use of a selected set of frequently used herbs with known HDIs with regular medications. If a selected herb was used, the herb and oncological medication were assessed for potentially relevant HDIs. All potentially relevant HDIs were independently evaluated by two pharmacists on clinical relevance. Results: A total of 202 patients were included in the analysis. The mean age was 74 years and 54 % was male. The prevalence of potentially relevant HDIs was 4 % and overall herb use was 12 %. Thirteen potentially relevant HDIs were identified, of which 6 were judged to be clinically relevant. The clinically relevant HDIs concerned red yeast rice, red coneflower, turmeric, and cannabis. None of the patient characteristics were associated with overall herb use. Conclusion: Potentially relevant HDIs between herbal supplements and oncological treatment occur in 4 % of older adults with cancer and half of these are clinically relevant. Healthcare providers should question patients with cancer on the use of herbal supplements and monitor for relevant HDI with the treatment given.
UR - http://www.scopus.com/inward/record.url?scp=105000803720&partnerID=8YFLogxK
U2 - 10.1016/j.rcsop.2025.100585
DO - 10.1016/j.rcsop.2025.100585
M3 - Article
C2 - 40212889
AN - SCOPUS:105000803720
SN - 2667-2766
VL - 18
JO - Exploratory Research in Clinical and Social Pharmacy
JF - Exploratory Research in Clinical and Social Pharmacy
M1 - 100585
ER -
